Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
I guess we'll find out tomorrow if any big news is up Eric's sleeve. The accounts were only 4 working days late, and so intriguing Eric decided to suspend shares on the 1st May, rather than simply annouce they would be one week late because of audit delays, unforeseen circumstances beyond their control, unrelated to cash flow and/or economic position.
The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently, and so an RNS confirming this will be very well received, but still hoping for something even bigger and the reason for the ongoing suspension, despite the release of the accounts, whereby it stops those in the know and their mates from buying in before the event. Just a thought, but any major player/investor would certainly prefer it that way I reckon. Anyways, regardless of what may come, Genflow’s prospects and potential are looking very nice and I for one will be holding and adding for great things to come. Gla :-)
Genflow Biosciences Plc, a biotechnology company focusing on longevity research and age-related diseases, has released its final results for the year ending 31 December 2023. The company has received significant non-dilutive research grants from the Government of Wallonia in Belgium, completed a successful fundraise, and made strategic progress with its key research programs in MASH and Werner Syndrome. These achievements, alongside the expansion of their intellectual property portfolio and collaborations with other biotech firms, highlight Genflow’s commitment to advancing its research pipeline and financial stability.
Nice one Porter, and great if Eric has more good news to deliver. Gl :-)
Cheers MumbleG, certainly hidden away, but very encouraging nonetheless, nothing we didn't know although underlines exciting prospects and potential going forward. Gl :-)
Cheers Steg, I'm out and about today I can't seem to access it on my mobile. Fingers crossed Eric has got some big news ro go along with confirmation of the suspension being lifted. Gl holders...Excitement building!!! ;-)
7 May 2024
Genflow Biosciences Plc
("Genflow" or "the Company")
FINAL RESULTS
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce its final results for the year ended 31 December 2023. The Annual Report is available to view on the Company's website at www.genflowbio.com
The Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.
Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.
24/1/24
Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.
Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.
One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.
Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.
Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.
“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.
Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.
Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.
hTtps://longevity.technology/news/genflow-launches-two-grant-funded-longevity-research-programs/
EXO Biologics will direct the funding towards advancing transformative healthcare initiatives, including the enrolment in EVENEW, the first European Medicines Agency (EMA) authorized clinical trial involving MSC-based exosomes. This EVENEW study is a Phase 1/2 European clinical trial using EXO Biologics’ lead MSC-based exosome candidate EXOB-001. EXO Biologics is initially developing EXOB-001 to prevent Bronchopulmonary Dysplasia (BPD) in preterm newborns.
Directing resources toward enhancing the ExoPulse production platform will enable EXO Biologics to conduct further research into its longer-term aim of loading exosomes with therapeutic molecules such as RNAs, proteins, and chemical drug compounds.
In addition, EXO Biologics will use the funds to reinforce ExoXpert, EXO Biologics’ newly launched subsidiary and one of the first CDMOs specializing in exosomes, leveraging the clinically proven manufacturing platform ExoPulse. By offering access to ExoPulse, ExoXpert can accelerate and de-risk naive and loaded exosome drug development journeys for other companies.
hTtps://www.exobio.be/en/news/14_exo-biologics-secures-up-to-eur-16-million-in-series-a-funding-for-exosome-therapeutic-development-a
Genflow's other partner form the 2.89m Euro grant has just raised a further 16m Euros.and their press release ould appear to be good news for Genflo going forward. Gla ;-)
EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.
The funding will primarily strengthen EXO Biologics’ subsidiary ExoXpert®, the exosome specialist CDMO, support the first EMA approved MSC-derived exosome clinical trial, and fund the ongoing development of the ExoPulseTM platform to produce unmodified and RNA or drug-loaded exosomes.
Liège, Belgium April 24, 2024 – EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, today announces the successful securing of a total of up to EUR 16 million in Series A funding. EXO Biologics will use the funds to support its ongoing and future clinical trials. It will also use funds to continue its manufacturing expansion, including upgrading its unique production platform, ExoPulse, and expanding partnerships to enable pan-market access to the platform and GMP clinical grade exosomes for faster access to clinical trials.
“By achieving this Series A funding in what remains a challenging time across the life science sector, EXO Biologics has received an endorsement from its founders, existing and new investors. This significant investment will support EXO Biologics in obtaining non-dilutive funding. It will also enable EXO Biologics to bring novel exosome therapies to patients with few alternative therapeutic options,” said Hugues Wallemacq, Chief Executive Officer (CEO) of EXO Biologics. “Having now launched the first clinical trial approved by the EMA to use MSC-based exosomes, EXO Biologics is now able to support the clinical development of these highly promising therapies globally. This significant funding will therefore enable EXO Biologics to accelerate development and commercial agreements with third parties worldwide.”
EXO Biologics initially raised EUR 9 million from investors, including Noshaq, Founders, and Belgian Family Offices. This support allowed EXO Biologics to add substantial additional funding in the form of subsidies from the Public Service of Wallonia (SPW) in Belgium, amounting up to a further EUR 7 million.
A significant portion (EUR 5.5 million) of the public subsidies has been granted via the Technological Innovation Partnership for Advanced Therapy Medicinal Products (ATMP-PIT) initiative. This three-year program has been launched by BioWin and the SPW under the Walloon Recovery Plan in Belgium. It involves 26 partners and will fuel collaborations between academia, research institutions, and businesses, driving forward the development and manufacturing of next-generation biomedicines.
EXO Biologics will direct the funding towards advancing transformative healthcare initiatives, including the enrolment in EVENEW, the first European Medicines Agency (EMA) authorized clinical t
Revatis
772 followers
1w
Exciting News! Collaboration Alert at Revatis!🔬
We are delighted to announce the expansion of the collaboration between #Trince and #Revatis, marking a significant milestone in our journey. Together, we are proud to introduce the first photoporation platform in Wallonia, developed as part of the Mitosir project under the "BioWin-ATMP collaborative project."
The Mitosir project is dedicated to tackling muscular mitochondrial dysfunction seen in sarcopenia, a significant health issue. For this purpose, we have joined forces with #Genflow, a distinguished industrial partner known for their expertise and intellectual property in Sirtuin peptides, which are essential for mitochondrial function and anti-aging.
We're confident this collaboration will propel research in the realm of muscle health, and we're proud to work in tandem with ULB and the Uliege to explore the fundamental aspects of this critical topic.
Keep an eye out for more thrilling updates on this project! 💪💡
#stemcells #cellgenetherapy #MuscleHealth #Research #Innovation #Revatis #Trince #Genflow #ULB #Uliege #Rise #Photoporation #MitochondrialDysfunction #Sarcopenia #Biowin #wallonierelance
...............
Revatis
772 followers
1d
A nice paper authored by Julien Duysens, our PhD student within the company, made possible through a grant from Wallonia.
Didier Serteyn
Professor Liege University
1d
Latest Development: In our pursuit of advancing tissue engineering and extra cellular Vesicles (exosomes) production, we're working towards a significant milestone. While our goal of harvesting 1 billion muscle derived MSCs (#revatis) from a single muscle microbiopsy (10 mg) at P3 is ambitious, we're making progress step by step.
Stay tuned for updates on our journey! #stemcells #tissueengineering #regenerativemedicine #cellandgenetherapy #equinehealth #exosomes #extracellularvesicles
"be the first to know about our groundbreaking advancements"......sounds encouraging!!! Gla ;-)
Interesting for Genflow to post the following on Linkedin a couple of hours after suspension. Gla -)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,594 followers
6h
Stay up-to-date with Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!
Sign up for our latest updates and be the first to know about our groundbreaking advancements. Don't miss important news & exclusive insights - subscribe now: hTtps://loom.ly/ViGV0h8
#GENF #GENFF #biotech #genetherapy #aging
Hopefully so Northeast, but could be something and nothing, although not sure how many other listed companies would as ask for a suspension because the Audit process was taking longer than plannned, and so very intriguing Genflow confirmed "the delay is not related to the Company's cash flow or other underlying economic position". Very interesting and somewhat exciting as we await their next update....it would be amazing if some other party have their financial accounts under due diligence, hence the delay...just a thought. Gl :-)
What Is Due Diligence?
Due diligence is an investigation, audit, or review performed to confirm facts or details of a matter under consideration.
In the financial world, due diligence requires an examination of financial records before entering into a proposed transaction with another party.
Lol Porter, stranger things have happened but I'm sure your realistic opinion on due diligence is correct, unless the due diligence is from a JV partner and or T/O approach, " and other unforeseen circumstances out of its control " is certainly intriguing. Hopefully shouldn't take too long before the re-listing when everything will be made clear. Gl :-)
Every chance Northeast............Take over looming????? Gl -)
" due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control"
Excitement building , ust gone UP a notch!!! Gla ;-)
Genflow Biosciences Plc
Temporary Suspension of Listing pending publication of Annual Financial Report
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, provides the following update in relation to the publication of its Annual Financial Report ("Annual Report").
The Company was required to publish its Annual Report for the financial year ending 31 December 2023 by 30 April 2024. However, due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control, the Company requires a short amount of additional time. The delay is not related to the Company's cash flow or other underlying economic position.
As a result, at the Company's request, the listing of the Company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended with effect from 7.30 a.m. on 1 May 2024 pending publication of the Annual Report.
More buys than sells although the 1m yesterday was timed at 4.35pm and so anyone's guess and the 1.5m sell was timed at 2.08pm yesterday, which was directly followed by 5 x 100k buys and 5 x 200k buys, and so obviously soaked up immediately or even could have been a Bed & ISA , whereby they couldn't execute in one hit because of the demand, and the reason the flurry of buys thereafter. Anyways, all in the mix regardless and no doubt given how the majority of shares are now very tightly held as the free float gets smaller, the demand for shares will continue and the sp will continue its upward momentum, in anticipation of great things to come. Gl :-)
Every chance Porter, and the $1 Billion deal announced last week is the most exciting and most interesting and relevant to Genflow, given their planned phase 1/11 clinical trial in NASH...R&D focussed on the liver is hot hot hot at the moment, and so would a Major Pharma wait for trial resultsor get in early on the back of stellar pre-clinical studies, which were expected end of 2023!!!??? .Gl :-)
UK biotech signs $1bn deal to develop liver disease drugs
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Ian Johnston 14 HOURS AGO
German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.
Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.
The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.
https://www.ft.com/content/3cd4fc3c-e52b-4042-9540-08ce2444b5bd
2p plus and more on its way, Final Results expected soon and every chance Eric will have an update or two on proceedings. Excitement building!!! Gl :-)
Hopefully someone in the know Porter. :-)))